Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults
Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults
On Tuesday, Valneva SE (NASDAQ:VALN) revealed antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ.
週二，Valneva SE（納斯達克股票代碼：VALN）在接種單劑基孔肯雅疫苗IXCHIQ三年後公佈了抗體持久性數據。
The results align with Valneva's expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated.
結果與Valneva對該疫苗的期望一致，證實了所有受調查年齡組的抗體都具有強而持久的持久性。
The three-year persistence data align with the twelve-month and two-year persistence data the company reported in December 2022 and 2023, respectively.
三年持久性數據與該公司分別在2022年12月和2023年12月報告的十二個月和兩年的持久性數據一致。
Also Read: European And US Vaccine Stocks Are Under Pressure – Here's Why
另請閱讀：歐洲和美國的疫苗庫存面臨壓力——這就是原因
Among the 278 healthy adults still enrolled in the trial, 96% maintained neutralizing antibody titers well above the seroresponse threshold three years after the single-dose vaccination. The primary endpoint was, therefore, met.
在仍在參加該試驗的278名健康成年人中，有96％的人在單劑量疫苗接種三年後保持了遠高於血清反應閾值的中和抗體滴度。主要終結點是萬億.erefore，met。
The persistence of antibodies in older adults (age 65+) in terms of geometric mean titers (GMTs) and seroresponse rates (SRRs) was comparable to younger adults (18-64 years of age).
就幾何平均滴度（GMT）和血清反應率（SRR）而言，老年人（65歲以上）抗體的持久性與年輕人（18-64歲）相當。
No safety concerns were reported or identified during the two-year follow-up, and no Adverse Event of Special Interest were ongoing during participant enrollment in the trial.
在爲期兩年的隨訪中，沒有報告或發現任何安全問題，在試驗參與者入組期間，沒有發生任何特別關注的不良事件。
IXCHIQ is the world's first and only licensed chikungunya vaccine.
IXCHIQ是世界上第一個也是唯一獲得許可的基孔肯雅疫苗。
The vaccine is currently approved in the U.S., Europe, and Canada to prevent disease caused by the chikungunya virus in individuals 18 and older.
該疫苗目前已在美國、歐洲和加拿大獲得批准，用於預防18歲及以上人群由基孔肯雅熱病毒引起的疾病。
Valneva recently submitted label extension applications to the FDA, the European Medicines Agency, and Health Canada to potentially extend the use of its chikungunya vaccine IXCHIQ to adolescents aged 12 to 17 years.
Valneva最近向美國食品藥品管理局、歐洲藥品管理局和加拿大衛生部提交了標籤延期申請，以期有可能將其基孔肯雅疫苗IXCHIQ的使用範圍擴大到12至17歲的青少年。
Juan Carlos Jaramillo, Chief Medical Officer of Valneva, said, "We are extremely pleased about these three-year data which further highlight IXCHIQ's differentiated product profile and ability to induce a robust, long-lasting antibody response in both younger and older adults with a single vaccination."
Valneva首席醫學官胡安·卡洛斯·哈拉米洛說：「我們對這些爲期三年的數據感到非常高興，這些數據進一步突顯了IXCHIQ的差異化產品特徵，以及通過單次疫苗在年輕人和老年人中誘發強大、持久的抗體反應的能力。」
In September, Valneva and Pfizer Inc. (NYSE:PFE) released immunogenicity and safety data from their VLA15-221 Phase 2 study following a second booster vaccination of their Lyme disease vaccine candidate, VLA15, given one year after receiving the first booster dose.
9月，Valneva和輝瑞公司（紐約證券交易所代碼：PFE）發佈了其 VLA15-221 2期研究的免疫原性和安全性數據，此前他們的萊姆病候選疫苗 VLA15 在接種第一劑加強疫苗一年後進行了第二次加強接種。
One month after receiving the second booster dose, the immune response and safety profile of VLA15 were similar to those reported after receiving the first booster dose, showing compatibility with the anticipated benefit of a booster vaccination before each Lyme season.
在接種第二劑加強劑量一個月後，VLA15 的免疫反應和安全狀況與接受第一劑加強劑量後報告的免疫反應和安全狀況相似，顯示出與每個萊姆季節之前加強疫苗的預期益處相容。
Price Action: VALN stock is up 2.58% at $3.97 at last check Tuesday.
價格走勢：在週二的最後一次檢查中，VALN股價上漲2.58％，至3.97美元。
- Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
- 儘管在2024年遭受挫折，摩根士丹利仍保持樂觀的醫療科技前景，升級了Intuitive Surgical和Stryker的評級，下調了Nevro和Glaukos的評級
Image via Shutterstock.
圖片來自 Shutterstock。
